Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Court blesses combination of statements and disclosures that must accompany Vascepa promotions in a ruling that rejects FDA's narrow interpretation of 2012 Caronia case.
You may also be interested in...
Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.
Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.
Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.